\n\n\n\n\t\t\n\t\t\tProteolix\n\t\t\thttp://www.proteolix.com/\n\t\t
\n\t\t\n\t\t\tWatch Company\n\t\t\tGet Widget\n\t\t
\n\tProteolix, Inc. is a biopharmaceutical company dedicated to discovering, developing and marketing pharmaceutical products that target certain cancers and immunological conditions by inhibiting the...More»
\n\t\t\tProteolix, Inc. is a biopharmaceutical company dedicated to discovering, developing and marketing pharmaceutical products that target certain cancers and immunological conditions by inhibiting the proteasome and thereby disrupting protein turnover in cells. In addition to its lead product candidate, carfilzomib (PR-171), which is delivered intravenously and is currently in multiple clinical trials to evaluate its safety and efficacy in multiple types of cancer, Proteolix is developing next generation proteasome inhibitors, including an oral proteasome inhibitor and a selective immunoproteasome inhibitor, to expand the therapeutic potential of this new target class. Proteolix is headquartered in South San Francisco.
(Source:www.proteolix.com)«Less
Overview
\n\t\t\t\tLocation: \tSouth San Francisco, CA, United States\n
\n\t\t\t\tIndustry: Biopharmaceuticals
\n\t\t\t\tTags:\n\t\t\t\tbiotech therapeutics,\n\t\t\t\tcure,\n\t\t\t\timmunological conditions,\n\t\t\t\tcancer,\n\t\t\t\tcarfilzomib,\n\t\t\t\tbiotech\n\t\t\t\t
\n\t\t\tFinancials
\n\t\t\t\tLatest Funding: Series B - $45M (05/2006)
\n\t\t\t\tInvestors:\n\t\t\t\t\t\n\t\tDelphi Ventures\n\t\t\t\t
\n\t\t\tMarket
\n\t\t\t\tCompetitors:\n\t\t\t\t\t\tNereus Pharmaceuticals\n\t\t\t\t
\n\n\t\t\t\tRelated Companies:\n\t\t\t\t\tOncoMed Pharmaceuticals\n\t\t\t\t
\n\t\t\t